Geron Q1 Earnings Call Highlights Geron logo MarketBeat May 6, 2026 8 min read GERN Key Points Q1 net revenue of $61.8 million (up 31% YoY) and Geron reiterated full‑year Rytelo guidance of $220–240 million, noting growth is weighted to H2 2026 while gross‑to‑net rose to 21% (expected low‑mid 20s for the year) due to wider 340B use and expanded GPO contracting. U.S. commercial execution is scaling — Rytelo now reaches about 1,450 prescribing accounts with 6% QoQ demand growth; the company is prioritizing the ~8,000‑patient second‑line lower‑risk MDS market and imetelstat's inclusion in the NCCN chemotherapy order template positions it as the preferred second‑line option. Pipeline and international plans: the fully enrolled Phase 3 IMpactMF trial is expected to hit its interim overall‑survival event trigger in H2 2026 (final analysis base case H2 2028), Geron is evaluating European commercialization pathways with an update planned before year‑end, and it ended Q1 with about $341 million in cash after lower operating expenses.
Interested in Geron Corporation? Here are five stocks we like better. Geron Corporation: FDA Approval Fuels Stock Price Surge Geron (NASDAQ:GERN) reported first-quarter 2026 net revenue of $61.8 million, up 31% year-over-year and 8% quarter-over-quarter, as the company continued to scale commercialization of Rytelo in the U.S.
Management reiterated full-year 2026 guidance and outlined ongoing work to evaluate a European commercialization approach, while also previewing expected milestones for its Phase 3 myelofibrosis program. Rytelo revenue growth and 2026 guidance reiterated Chief Executive Officer Harout Semerjian said Geron made progress on its 2026 strategic priorities in the quarter by growing Rytelo through "focused commercial execution" and advancing its European strategy "while maintaining our financial discipline." → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries Geron Stock Doubles After Imetelstat Receives FDA Panel Approval Chief Financial Officer Michelle Robertson said total net revenue for the three months ended March 31, 2026 was $61.8 million, compared with $39.6 million in the prior-year period. Geron reiterated its 2026 net revenue guidance for Rytelo of $220 million to $240 million, with Robertson noting that "a greater portion of growth" is anticipated in the back half of the year.
Robertson also highlighted a shift in gross-to-net dynamics as volume increased. Gross-to-net reductions rose to 21% in the quarter from 13% a year earlier, driven by "wider 340B utilization and expanded GPO contracting." For the rest of 2026, she said the company expects gross-to-net to be in the "low to mid 20s." Story Continues U.S. commercial execution focuses on second-line lower-risk MDS → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Chief Commercial Officer Ahmed ElNawawi said first-quarter demand grew 6% quarter-over-quarter and that prescribing accounts increased approximately 12%, expanding the company's footprint since launch to about 1,450 accounts. ElNawawi said Geron estimates the second-line lower-risk MDS opportunity at roughly 8,000 patients in the U.S., calling that segment the company's "primary commercial focus" and noting the strategy is supported by current NCCN guidelines.
He added that the company is seeking to reach patients "at the right point in their treatment journey when they are most likely to benefit." → Tyson Foods' Total Returns: Tasty Treats for Income Investors? He described three core commercial initiatives: Targeted engagement with high-volume community accounts, prioritizing centers treating earlier-line and second-line patients while also using digital tactics for lower-volume accounts. Increased investment in marketing channels, with an emphasis on digital, non-personal promotion, and third-party educational platforms to create a "3-D surround sound" approach.
Cross-functional account management that uses data presented at ASH 2025 to address cytopenias and position Rytelo as standard of care in appropriate second-line patients, "regardless of their RS." On utilization by line of therapy, ElNawawi said first- and second-line patient starts on a rolling 12-month basis were 33% in the quarter. In the Q&A, management said this compares with 30% previously (also on a 12-month look back), and characterized the trend as "continuous progress." Asked about the sustainability of first-quarter demand growth, Semerjian said the company plans to "continue to grow quarter over quarter," and reiterated that Geron expects growth to accelerate in the second half of 2026, in part because changes made in the fourth quarter and first quarter "need time to kick into action." Medical affairs highlights: conference presence, NCCN order template, and real-world evidence timing Executive Vice President of Research and Development and Chief Medical Officer Dr. Joseph Eid said Geron continued engaging with the hematology community to increase Rytelo's "share of voice," citing participation at meetings including the Aplastic Anemia & MDS International Foundation, ASCO, and the 2026 Pan-Hematology Clinical Updates meeting.
Extract — continue reading at the source.
